Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Aethlon Medical Inc (AKA: Bishop Equities Inc)
Profile last edited on: 6/6/2024      CAGE: 47A31      UEI: MUNVGHPLRV56

Business Identifier: Removal of disease-causing particles (viral pathogens and tumor-secreted exosomes), from circulatory system
Year Founded
1998
First Award
2017
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

11555 Sorrento Valley Road Suite 203
San Diego, CA 92121
   (619) 941-0360
   info@aethlonmedical.com
   www.aethlonmedical.com
Location: Multiple
Congr. District: 50
County: San Diego

Public Profile

Aethlon Medical, Inc. is a medical technology company focused on products development targeted to diagnosis and treatment of life- and organ threatening diseases. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. Also under development is TauSome - an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
1
Conversion Rate
33.33%
Phase I Dollars
$597,695
Phase II Dollars
$1,860,561
Total Awarded
$2,458,256

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : AEMD
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 2 NIH $1,860,562
Project Title: A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring
2018 1 NIH $298,444
Project Title: The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
2017 1 NIH $299,250
Project Title: Device Strategy for Selective Isolation of Oncosomes and Non Malignant Exosomes

Key People / Management

  Charles J Fisher Jr -- Chief Executive Officer and Director

  James A Joyce -- Founder, CEO, Sec. & Director

  Rodney S Kenley -- President & Director

  Lisa M Boswell -- Director, Quality Systems and Regulatory Affairs

  Guy F Cipriani -- Sr. VP, Chief Bus. Officer & Director

  James B Frakes -- CFO & Senior VP of Finance

  Michael Jacobs -- Associate Director of Manufaturing & Product Development

  Steven P Larosa -- Chief Medical Officer

  Annette Marleau -- Director of Research

  Sunil Sawhney -- Head of Clinical Studies

  Thomas L Taccini -- Vice President, Manufacturing and Product Development

Company News

There are no news available.